The Imaging Consortium for Drug Development (ICD) is a collaborative research effort between academia and pharmaceutical companies who are developing novel drugs to treat central nervous system (CNS) disorders, initially focusing on pain and analgesia.

Aims

• To conduct basic and applied research activities, both preclinical and clinical in order to lead to research advances that will facilitate the development of useful pharmaceutical products, for the treatment of pain and other disorders.
  
  
• To define standards that may be used in clinical trials for evaluating novel analgesics
  
  
• To establish an fMRI based database for human and animal imaging of analgesics and disease states.

		icd 1 - proof of concept studies The utility of functional magnetic resonance imaging (fMRI) in humans for the evaluation of drug (efficacy or side effects) or disease state.
		icd 2 - translational studies In this category, studies consist of basic research intended to develop protocols, procedures and technologies for using fMRI to evaluate drug or disease state in animal models and surrogate human models of pain.
		icd 3 - novel drug evaluation studies In this category, research may be performed with members using fMRI protocols, procedures, and technologies (e.g., evaluation of a new drug).
relevant p.a.i.n. group publications
relevant non-pubmed p.a.i.n. group publications